AMO to be acquired by Abbott

Article

Advanced Medical Optics (AMO) has been acquired by Abbott, a global pharmaceutical and medical device company, the companies have announced in a statement.

Advanced Medical Optics (AMO) is to be acquired by Abbott, a global pharmaceutical and medical device company, the companies have announced in a statement. The $2.8 billion acquisition is expected by both companies to be completed in the first quarter of this year.

Abbott, one of the world's largest healthcare companies, currently has no presence in the ophthalmic market, although it markets its products in 130 countries globally. The acquisition will allow Abbott to take advantage of AMO's leading position in the LASIK surgical devices market, and to capitalize on the company's top-three position in the cataract surgical devices and contact lens care products markets.

Abbott will acquire AMO at $22 per share in a cash transaction, commencing on January 26, 2009. Jim Mazzo, the current chairman and chief executive officer of AMO will remain as AMO's president when the acquisition is complete.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.